Fresenius Medical Care AG - FMS STOCK NEWS

Fresenius Medical Care and CytoSorbents have enhanced their partnership through a multi-stage collaboration aimed at innovating and expanding sales opportunities in critical care. This three-year agreement will see Fresenius Medical Care actively market CytoSorb as a primary blood purification therapy for critical conditions, excluding the U.S. The collaboration promises to leverage various marketing strategies to increase the visibility of CytoSorb while ensuring its compatibility with Fresenius Medical Care's existing platforms. This initiative is expected to drive growth and enhance patient care.

Fresenius Medical Care North America has launched the CombiSet SMARTECH, an innovative single-use bloodline featuring the integrated Crit-Line® blood chamber (CLiC™). This design simplifies hemodialysis setup by minimizing manual connections and enhancing fluid management for patients. The technology continuously monitors critical parameters, supporting timely interventions by clinicians. The new bloodline aims to improve patient care in outpatient and acute settings, thereby reinforcing Fresenius's commitment to innovation in renal therapies.

Fresenius Medical Care launched the My Reason® campaign to enroll over 100,000 participants in a kidney-focused genomics registry over five years. The initiative aims to better understand genetic variations linked to chronic kidney disease (CKD) and end-stage kidney disease (ESKD). By linking genomic and clinical data, the registry seeks to enhance diagnostic precision and individualize treatment. Eligible patients can enroll through Fresenius Kidney Care dialysis centers. The move aligns with Fresenius's strategy to leverage digital technologies in renal therapy.

Fresenius Medical Care appoints Dr. Nwamaka (Amaka) Eneanya as Head of Strategy and Operations for its Global Medical Office. Dr. Eneanya, a nephrologist from the University of Pennsylvania, will enhance healthcare outcomes for kidney disease patients. Her expertise in health equity and patient engagement aligns with the company’s strategic goals. Notably, she contributed to a pivotal publication advocating for removing race from kidney function algorithms, influencing national medical standards. Fresenius operates 4,171 clinics, serving 345,000 patients globally, with stock listed as FMS on the NYSE.

Fresenius Medical Care announced the social media expansion of its Corporate Social Responsibility initiative, The Kidney Kid, aiming to reach millennial parents. This initiative, launched on World Kidney Day 2022, focuses on educating children about kidney health. The campaign includes partnerships with organizations like the Boys & Girls Clubs of America and will utilize platforms such as Facebook and Instagram. The goal is to bridge the knowledge gap on kidney health, especially in regions with low health literacy.

Fresenius Medical Care has been awarded the ACHS Global Quality Improvement Award for its WeAudit program, enhancing patient care in 290 dialysis clinics across 10 Asia Pacific markets. The program effectively replaced manual audits with an electronic system, improving compliance and quality of care. Following a successful pilot in Singapore, WeAudit has streamlined data collection and reporting using hand-held devices, allowing for real-time monitoring and strategic planning. This recognition underscores the company's commitment to patient-centered care.

Fresenius Medical Care announced the launch of 'Carrie', a mobile app designed to support its nurses and clinical teams across Asia Pacific. The app promotes nurse engagement, job satisfaction, and career development while enhancing patient care. Studies indicate that higher nurse engagement correlates with improved patient safety and experience, potentially increasing profitability for healthcare facilities. Initially available in Australia, Hong Kong, the Philippines, and Singapore, the app will be expanded regionally.

Fresenius Medical Care showcased its innovative home dialysis solutions at the China International Import Expo in Shanghai. This includes the 5008S hemodialysis machine and a new automated peritoneal dialysis machine, both supported by the DiaSmart therapy data management system. With around 10.06% of adults suffering from chronic kidney disease in China, home dialysis offers flexibility and enhanced quality of life, particularly post-COVID-19. The company aims to make home dialysis a viable option for patients, expanding access and improving healthcare outcomes.

Fresenius Medical Care has entered a strategic distribution partnership with JMS Co. Ltd to distribute innovative home dialysis therapies in Japan. This initiative addresses the growing need for dialysis treatment in Japan’s aging population, projected to have 33% aged 65 and over by 2035. Currently, only 3% of dialysis patients in Japan use home therapies, the lowest in the developed world. The partnership aims to enhance quality of life through flexible treatment options, allowing patients to manage their care at home.